Articles On Neurotech International (ASX:NTI)

Title Source Codes Date
Weed Week: Getting a grip on the cannabis scene amid a pending regulatory shakeup

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

Stockhead NTI 2 days ago
NTI’s trial of Autism treatment in children shows further patient improvement after 12 weeks.

There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.

nextinvestors.com NTI 1 week ago
Closing Bell: ASX ends almost okay after Telstra-led recovery

ASX 200 closes 0.16pc lower after modest rally from morning lows  Six of 11 sectors lower, after rate-sensitive sectors improve after lunch  Killi Resources surges again with a late surge to dethrone Infini   Local markets have trimmed...

Stockhead NTI 1 week ago
Neurotech reports further positive Phase 2/3 autism trial results

Neurotech reports further benefits from Phase 2/3 trial of NTI164 in autism patients Patients showed 56% improvement in CGI-S score from baseline at week 12 Patients unblinded at end of week eight showed 21% improvement in CGI-S score to w...

Stockhead NTI 1 week ago
Market Highlights: More dull records for Wall St and 5 ASX small caps to watch

ASX 200 pointing to a lower start  NVDA adds another 2% as more Wall St records tumble Base metals mostly fell overnight    Aussie markets might have to wallow in red for a bit this morning, despite more of the same in terms of fresh reco...

Stockhead NTI 1 week ago
Closing Bell: The benchmark strikes back as Telstra leads broad based gains

ASX 200 rises strongly on Tuesday, closes up +0.86pc  All 11 sectors in the green, like Kermit on a golf course  Top small cap was Killi Resources with a bumper +83.7pc surge   Local markets jumped on Tuesday, erasing all of Monday’s l...

Stockhead NTI 1 week ago
Neurotech forms expert panel after TGA meeting

  Neurotech International to establish expert PANDAS/PANS Advisory Group Advisory group follows productive pre-submission meeting with TGA NTI’s lead drug NTI164 is showing promise in treatment of PANDAS/PANS   Special Report: Neurotech I...

Stockhead NTI 2 weeks ago
Closing Bell: Tech, Energy weigh down ASX; Schrole up almost 200pc on acquisition deal

Aussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails ahead of RBA rates decision Chinese Premier Li Qiang meets PM in Canberra today   Aussie stocks had a lacklustre start to the week on Monda...

Stockhead NTI 1 month ago
Neurotech’s autism treatment reaches two-year trial milestone

  Neurotech International says ASD patients in its Phase 1/2 trial of NTI164 have now been on treatment for more than two years Initial positive results of the Phase 1/2 ASD trial have been a catalyst for the Phase 2/3 ASD study NTI164 is...

Stockhead NTI 1 month ago
Closing Bell: A very hot ASX banks on big banks after big central banks start cutting

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

Stockhead NTI 1 month ago
Neurotech’s cannabinoid drug blazes new path for treating rare neurological disorder in kids

Neurotech reports improvements in PANDAS/PANS patients after 52 weeks of NTI164 treatment The study highlights the safety profile of NTI164 and its potential as a therapy for the disease Caregivers express gratitude for significant progres...

Stockhead NTI 1 month ago
Closing Bell: ASX gains as house prices keep climbing; cash is dead as Armaguard falters

ASX starts June positively, extending May gains  Property prices in Australia rose by 0.8% in May, with Sydney remaining the most expensive city Lovisa plunges by -10% as John Cheston takes over as CEO   The ASX has started the month of...

Stockhead NTI 1 month ago
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1

Bell Potter says biotech very much a non-cyclical performer driven by catalysts including clinical trial data Radiopharmaceutical-focused Clarity Pharmaceuticals has risen 76% YTD after promising trial results Merchant Funds is bullish on...

Stockhead NTI 2 months ago
NTI’s Phase I/II Rett Syndrome clinical trial results improve upon $2.4BN capped Neuren’s results…

Our biotech Investment, Neurotech International (ASX: NTI) just announced additional data from its Rett Syndrome clinical trial today.

nextinvestors.com NTI 2 months ago
Neurotech International’s world-first vision to treat neurological disorders in children with cannabinoid drug

A listed Australian biopharmaceutical development company says it has the potential to provide the world’s first approved cannabinoid drug therapy for neurological disorders, like autism, in children.

The West NTI 2 months ago
Closing Bell: ASX up as unemployment rate ticks higher; BHP, Nimy Resources gain

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Stockhead NTI 3 months ago
Weed Week: A VAST majority of Americans now want marijuana to be legal

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Stockhead NTI 3 months ago
Closing Bell: ASX selloff softens… then pummels again last minute; Rinehart ups stake in Lynas

The ASX rebounded from a sluggish start… but wait, it all dipped again as we were heading out the door Local traders were initially shaken this morning after remarks from Fed’s Powell Aussie defence budget to be given a $50bn boost   The...

Stockhead NTI 3 months ago
Neurotech reports positive top-line Phase 1/2 Rett Syndrome clinical trial results

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Stockhead NTI 3 months ago
NTI’s two clinical trial results are in - Treatment success for BOTH Autism AND for Rett Syndrome

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.

nextinvestors.com NTI 3 months ago
Neurotech International completes last patient’s trial for Autism Spectrum Disorder

Neurotech International (ASX:NTI), has attained a new milestone in its clinical trial for Autism Spectrum Disorder (ASD) – as it now confirms its 54th and final patient has completed their last visit for the Phase II/III NTIASD2 clinical tr...

themarketonline.com.au NTI 3 months ago
Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final...

smallcapsau.mystagingwebsite.com NTI 3 months ago
Market Highlights: Bullish predictions on gold and copper prices, and 5 ASX small caps to watch today

  Aussie shares set to rise again after a modest tick up on Wall Street Gold price hit a new high Bank of America’s bullish predictions on gold and copper prices   Aussie shares are set to rise again on Wednesday after Wall Street ticked...

Stockhead NTI 3 months ago
Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is be...

themarketonline.com.au NTI 3 months ago
TWO major share price catalysts… in the coming weeks

We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.

nextinvestors.com NTI 3 months ago
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Stockhead NTI 4 months ago
Neurotech International announces extension of NTI164 in female Rett Syndrome

Neurotech International (ASX:NTI) has announced the extension of its Phase 1/2 clinical trial investigating the use of NTI164 in female Rett Syndrome patients and an additional ethics approval.

BiotechDispatch NTI 4 months ago
Closing Bell: ASX ends higher but iron’s ordinary problem isn’t going away

  Local markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary stocks offset losses in materials and Energy  Small Caps led by LBT Innovations   It’s hard to stay afloat when BHP sinks to a near nine-m...

Stockhead NTI 4 months ago
Neurotech extends clinical trials for the $US2bn Rett Syndrome market

12-week Phase I/II clinical trial to treat Rett Syndrome with NTI164 broad spectrum cannabinoid drug therapy extended to 52 weeks All 14 female patients to receive NTI164 under care of Associate Professor Carolyn Ellaway Phase I/II 12 week...

Stockhead NTI 4 months ago
Neurotech International extends NTI164 Rett Syndrome trial to 52 weeks

Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week dura...

smallcapsau.mystagingwebsite.com NTI 4 months ago
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

Stockhead NTI 4 months ago
Closing Bell: Commodity prices, resurgent rate fears drag ASX to third straight loss

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...

Stockhead NTI 4 months ago
Neurotech International announces strong results from NTI164 PANDAS/PANS trial extension

Neurotech International (ASX: NTI) has announced “highly significant” improvements during the extension phase of a clinical trial into the impact of its lead candidate NTI164 on children with paediatric autoimmune neuropsychiatric disorders...

smallcapsau.mystagingwebsite.com NTI 4 months ago
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

Stockhead NTI 4 months ago
US Short Report questions Acadia’s safety - NTI’s competing treatment safety results due within 6 weeks

Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.

nextinvestors.com NTI 5 months ago
ASX Health Stocks: Immuron reports record sales for its diarrhoea drug, Travelan

Immuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for benefit of patients   Immuron’s record sales Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January pe...

Stockhead NTI 5 months ago
Neurotech International’s innovative autism spectrum disorder treatment receives 52-week trial extension

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received a 52-week extension to its trial of a potential medicinal cannabis plant extract treatment for children with autism spectrum disorder (ASD)...

smallcapsau.mystagingwebsite.com NTI 5 months ago
Market Highlights: Chipmaker Arm up 29pc, Bitcoin tops US$50k, and 5 ASX small caps to watch today

  ASX to rise as Dow Jones hits fresh record Chipmaker Arm rises by almost 30pc Bitcoin has topped US$50k   The ASX is poised to rise on Monday after a mixed session in New York. At 8am AEDT, the ASX 200 index futures contract was pointi...

Stockhead NTI 5 months ago
Neurotech International’s NTI164 continues to impress with safe long-term efficacy in paediatric ASD patients

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on the progress of its world-first Phase I/II clinical trial examining the daily use of proprietary broad-spectrum cannabinoid dr...

smallcapsau.mystagingwebsite.com NTI 5 months ago
Why these ASX firms are shying away from the pot stock label – Part Two

Neurotech says due to often negative publicity around cannabis companies it tends not to promote itself as one Neurotech taking drug development approach to lead product NTI164, meaning it will be registered as a prescription-only BOD Aust...

Stockhead NTI 8 months ago
Neurotech International receives $3.17 million R&D tax incentive refund for treatment of paediatric neurological disorders

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has been recognised for its breakthrough development in the proposed treatment of paediatric neurological disorders with the grant of a $3.17 million re...

smallcapsau.mystagingwebsite.com NTI 8 months ago
Q A: Neurotech’s Dr Thomas Duthy on commercialising NTI164 as a treatment for PANDAS/PANS

  Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves...

Stockhead NTI 8 months ago
Neurotech International accelerates specialist medical solutions for neurological disorders

Neurotech International (ASX: NTI) continues to make excellent progress in accelerating its specialist medical solutions for the treatment of neurological disorders. The company is refining the use of its NTI164 treatment to help overcome a...

smallcaps.wpenginepowered.com NTI 8 months ago
Neurotech treatment looks to be making a difference in children with PANDAS/PANS in Phase I/II clinical trial

Paediatric patients with PANDAS/PANS treated with Neurotech’s NTI164 showed marked improvements Anxiety and depression levels in patients reduced by 30% whilst severity of illness sees 18% improvement Results from genomic analysis of patie...

Stockhead NTI 9 months ago
In Case You Missed It: Lithium acquisitions and bumper nickel processing for Q3

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead NTI 9 months ago
Neurotech’s cannabinoid drug shows promise for treatment of PANDAS and PANS

Paediatric neurological disorders specialist Neurotech International (ASX: NTI) has received promising results from its trial of potential treatments for the Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Inf...

smallcaps.wpenginepowered.com NTI 9 months ago
Closing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastie

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Stockhead NTI 9 months ago
Neurotech International completes recruitment for NTI164 trial in Rett Syndrome

Clinical-stage biopharmaceutical company Neurotech International (ASX: NTI) has completed the recruitment of 14 patients into a Phase I/II clinical trial investigating the use of lead candidate NTI164 in females with Rett Syndrome. The 16-w...

smallcaps.wpenginepowered.com NTI 9 months ago
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

Stockhead NTI 9 months ago
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Stockhead NTI 9 months ago